Free Trial
LON:SNG

Synairgen (SNG) Share Price, News & Analysis

Synairgen logo
GBX 1.40 -0.60 (-29.87%)
As of 06:57 AM Eastern

About Synairgen Stock (LON:SNG)

Key Stats

Today's Range
1.06
1.75
50-Day Range
1.72
2.70
52-Week Range
1.06
10
Volume
4.96 million shs
Average Volume
1.33 million shs
Market Capitalization
£13.68 million
P/E Ratio
N/A
Dividend Yield
1.53%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016). The 220 patient trial comprises 100 patients to be initiated in hospital and 120 patients to be initiated in the home setting. A successful outcome will inform onwards progression of SNG001 in COVID-19 patients. Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com

Remove Ads
Receive SNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synairgen and its competitors with MarketBeat's FREE daily newsletter.

SNG Stock News Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Synairgen Share Chat (SNG)
See More Headlines

SNG Stock Analysis - Frequently Asked Questions

Synairgen's stock was trading at GBX 2.70 at the beginning of the year. Since then, SNG shares have decreased by 47.2% and is now trading at GBX 1.43.
View the best growth stocks for 2025 here
.

Synairgen plc (LON:SNG) posted its quarterly earnings results on Tuesday, September, 29th. The company reported ($3.11) earnings per share for the quarter.

Shares of SNG stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synairgen investors own include Lloyds Banking Group (LLOY), AstraZeneca (AZN), Alibaba Group (BABA), boohoo group (BOO), Barclays (BARC), VanEck Gold Miners ETF (GDX) and Legal & General Group (LGEN).

Company Calendar

Last Earnings
9/29/2020
Today
3/11/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:SNG
CIK
N/A
Fax
N/A
Employees
34
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-15,860,268.04
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 0.75 per share
Price / Cash Flow
1.90
Book Value
GBX 4.75 per share
Price / Book
0.30

Miscellaneous

Free Float
N/A
Market Cap
£13.93 million
Optionable
Not Optionable
Beta
-2.23
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (LON:SNG) was last updated on 3/11/2025 by MarketBeat.com Staff
From Our Partners